365 related articles for article (PubMed ID: 30181244)
1.
Jia D; Augert A; Kim DW; Eastwood E; Wu N; Ibrahim AH; Kim KB; Dunn CT; Pillai SPS; Gazdar AF; Bolouri H; Park KS; MacPherson D
Cancer Discov; 2018 Nov; 8(11):1422-1437. PubMed ID: 30181244
[No Abstract] [Full Text] [Related]
2. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
3. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.
Schaffer BE; Park KS; Yiu G; Conklin JF; Lin C; Burkhart DL; Karnezis AN; Sweet-Cordero EA; Sage J
Cancer Res; 2010 May; 70(10):3877-83. PubMed ID: 20406986
[TBL] [Abstract][Full Text] [Related]
4. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.
Sutherland KD; Proost N; Brouns I; Adriaensen D; Song JY; Berns A
Cancer Cell; 2011 Jun; 19(6):754-64. PubMed ID: 21665149
[TBL] [Abstract][Full Text] [Related]
5. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
6. Cells Lacking the
Oser MG; Fonseca R; Chakraborty AA; Brough R; Spektor A; Jennings RB; Flaifel A; Novak JS; Gulati A; Buss E; Younger ST; McBrayer SK; Cowley GS; Bonal DM; Nguyen QD; Brulle-Soumare L; Taylor P; Cairo S; Ryan CJ; Pease EJ; Maratea K; Travers J; Root DE; Signoretti S; Pellman D; Ashton S; Lord CJ; Barry ST; Kaelin WG
Cancer Discov; 2019 Feb; 9(2):230-247. PubMed ID: 30373918
[TBL] [Abstract][Full Text] [Related]
7. A crucial requirement for Hedgehog signaling in small cell lung cancer.
Park KS; Martelotto LG; Peifer M; Sos ML; Karnezis AN; Mahjoub MR; Bernard K; Conklin JF; Szczepny A; Yuan J; Guo R; Ospina B; Falzon J; Bennett S; Brown TJ; Markovic A; Devereux WL; Ocasio CA; Chen JK; Stearns T; Thomas RK; Dorsch M; Buonamici S; Watkins DN; Peacock CD; Sage J
Nat Med; 2011 Oct; 17(11):1504-8. PubMed ID: 21983857
[TBL] [Abstract][Full Text] [Related]
8. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
[TBL] [Abstract][Full Text] [Related]
9. FGFR1 Oncogenic Activation Reveals an Alternative Cell of Origin of SCLC in Rb1/p53 Mice.
Ferone G; Song JY; Krijgsman O; van der Vliet J; Cozijnsen M; Semenova EA; Adams DJ; Peeper D; Berns A
Cell Rep; 2020 Mar; 30(11):3837-3850.e3. PubMed ID: 32187553
[TBL] [Abstract][Full Text] [Related]
10. Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation.
Hellwig M; Merk DJ; Lutz B; Schüller U
Cancer Gene Ther; 2020 May; 27(5):294-300. PubMed ID: 31068675
[TBL] [Abstract][Full Text] [Related]
11. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
12. Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.
Semenova EA; Kwon MC; Monkhorst K; Song JY; Bhaskaran R; Krijgsman O; Kuilman T; Peters D; Buikhuisen WA; Smit EF; Pritchard C; Cozijnsen M; van der Vliet J; Zevenhoven J; Lambooij JP; Proost N; van Montfort E; Velds A; Huijbers IJ; Berns A
Cell Rep; 2016 Jul; 16(3):631-43. PubMed ID: 27373156
[TBL] [Abstract][Full Text] [Related]
13. SIRT3 increases cisplatin sensitivity of small-cell lung cancer through apoptosis.
Guo R; Li Y; Xue Y; Chen Y; Li J; Deng X; Su J; Liu Y; Sun L
Gene; 2020 Jun; 745():144629. PubMed ID: 32229158
[TBL] [Abstract][Full Text] [Related]
14. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Luszczek W; Cheriyath V; Mekhail TM; Borden EC
Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
[TBL] [Abstract][Full Text] [Related]
15. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.
Kaminskyy VO; Surova OV; Vaculova A; Zhivotovsky B
Carcinogenesis; 2011 Oct; 32(10):1450-8. PubMed ID: 21771726
[TBL] [Abstract][Full Text] [Related]
17. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
18. NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer.
Wu N; Jia D; Ibrahim AH; Bachurski CJ; Gronostajski RM; MacPherson D
Oncotarget; 2016 Sep; 7(36):57514-57524. PubMed ID: 27613844
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of lncRNA KCNQ1OT1 Improves Apoptosis and Chemotherapy Drug Response in Small Cell Lung Cancer by TGF-β1 Mediated Epithelial-to-Mesenchymal Transition.
Li D; Tong Q; Lian Y; Chen Z; Zhu Y; Huang W; Wen Y; Wang Q; Liang S; Li M; Zheng J; Liu Z; Liu H; Guo L
Cancer Res Treat; 2021 Oct; 53(4):1042-1056. PubMed ID: 33705625
[TBL] [Abstract][Full Text] [Related]
20. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
